Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.20
- Piotroski Score 4.00
- Grade Equal-Weight
- Symbol (CERT)
- Company Certara, Inc.
- Price $9.56
- Changes Percentage (-3.24%)
- Change -$0.32
- Day Low $9.55
- Day High $9.94
- Year High $19.87
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $18.00
- High Stock Price Target $28.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.39
- Trailing P/E Ratio -43.54
- Forward P/E Ratio -43.54
- P/E Growth -43.54
- Net Income $-55,357,000
Income Statement
Quarterly
Annual
Latest News of CERT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Gold will soar to record highs in the first year of Trump's term as uncertainty sparks a flight to safety, commodities expert says
According to commodities expert Jeffrey Christian, gold is expected to reach record highs by the end of January and could peak by 2026 due to uncertainties surrounding Trump's policies. Investors are ...
By Yahoo! Finance | 8 hours ago -
Fans limited who they can resell concert or sports tickets to thanks to new Massachusetts law
A new Massachusetts law gives Ticketmaster more control over ticket transfers, aiming to prevent scalping. Consumer groups oppose the law, arguing it limits fans' freedom. The law requires selling tic...
By CBS News | 9 hours ago -
Selena Gomez says she has to trick her way into auditions when casting refuses to consider her for certain roles
Selena Gomez reveals struggles breaking typecasting in Hollywood, facing challenges to prove herself in auditions. Despite obstacles, she uses tactics to secure roles and pursue diverse and compelling...
By Business Insider | 12 hours ago
